Biosimilars Roll-Out Propels Fresenius Kabi’s Growth

Firm Credits Biosimilars Contribution As Increases Seen In Q3

 
• By Dave Wallace
  
Fresenius benefited from biosimilars growth in the third quarter (Shutterstock)

More from Earnings

More from Products